CRISPRa sgRNA Design for RSPO2 Gene Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regulating hepatic stellate cell competence in liver fibrosis face challenges in modulating the Wnt signaling pathway without blocking it directly, which can lead to adverse effects.
Innovation Solution
A CRISPR-Cas9 system is designed to specifically activate the RSPO2 gene by constructing a recombinant lentivirus vector with a sgRNA targeting the RSPO2 gene, enhancing the Wnt/β-catenin signal pathway to regulate hepatic stellate cells without blocking the Wnt pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the Wnt signal pathway is directly blocked to suppress HSC proliferation and induce hepatic stellate cell death, then the competence of hepatic stellate cell is improved, but adverse biological effects occur due to the pathway's involvement in various biological processes
Solution Approach 1:
The patent introduces RSPO2 as an intermediary molecule that indirectly modulates the Wnt/β-catenin signaling pathway. Instead of directly blocking the pathway (which causes adverse effects), the CRISPR-Cas9 system is used to upregulate RSPO2 expression, which then acts as a mediator to regulate hepatic stellate cell competence through the pathway's natural mechanisms, thereby avoiding harmful side effects while achieving the desired therapeutic effect
Solution Approach 2:
The patent changes the regulatory parameter from direct pathway inhibition to indirect upregulation of RSPO2 expression. By using CRISPR-Cas9 to increase RSPO2 levels (a positive regulator of Wnt signaling), the system achieves modulation of hepatic stellate cell competence through parameter change rather than direct pathway blockage, thus avoiding the adverse biological effects associated with direct inhibition
2Manufacturing precision
If a sgRNA is designed to target the RSPO2 gene promoter region to activate gene expression, then the specificity of gene activation is improved, but the design complexity and precision requirements increase
Solution Approach 1:
The patent applies local quality by focusing the sgRNA targeting specifically on the promoter region of the RSPO2 gene rather than the entire gene sequence. This localized approach concentrates the editing activity where it is most needed (the promoter region for transcriptional activation), improving precision while managing complexity by limiting the target scope to a specific functional region
Solution Approach 2:
The patent employs preliminary action by using bioinformatics tools and databases to pre-screen and identify optimal sgRNA sequences that meet specific criteria (complementarity to promoter region, avoidance of off-target sites, appropriate GC content) before experimental validation. This preliminary computational design phase reduces the complexity of experimental optimization and ensures high precision from the outset
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CRISPR-Cas9 system effectively activates the RSPO2 gene, up-regulating biomarkers like α-SMA and Collagen I, promoting hepatic stellate cell competence and providing a means to study liver fibrosis effectively.
Implementation Method 1
The specificity of editing the target sequence by CRISPR is realized by the complementary identification of the target sequence
Implementation Method 2
The dCas9 is further merged with the transcription-regulation protein (VP64, P65, HSF1) to specifically activate (CRISPR activation, CRISPRa) the target gene expression
Data Source
AI summary
A method of constructing a specific CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats associated) to activate a RSPO2 (R-spondin 2) gene is disclosed in the present invention. The method comprises the following steps: designing a sgRNA (single guide RNA) of a specifically targeted human RSPO2 gene; constructing a CRISPR-Cas9 recombinant lentivirus vector of a specifically activated RSPO2 gene; and lentiviral packaging a CRISPR-Cas9 system of the specifically activated RSPO2 gene. The CRISPR-Cas9 system designed by the present invention activates the RSPO2 target gene expression and promotes the activation of the hepatic stellate cell.